Advanced Melanoma
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma.
... To our knowledge, this report pooling data from four melanoma trials is the largest and most comprehensive analysis to date of the safety profile of anti–PD-1 monotherapy. We found that ap- proximately 50% of ...
14
MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy
... With the discovery of BRAF-mutant melanomas, the development of new targeted therapeutics has increased tremendously in the last several years. These drugs hold great potential in improving the prognosis of ...
10
Neoadjuvant therapy for locally advanced melanoma: new strategies with targeted therapies
... An exploratory trial using preoperative ipilimumab in histologically proved, locally advanced melanoma is in progress at the University of Pittsburgh. After biopsy, two doses of ipilimumab 10 mg/kg were ...
7
Challenging the standard of care in advanced melanoma: focus on pembrolizumab
... II trial enrolled 540 patients and randomized them equally to one of the three treatment arms, pembrolizumab 10 mg/kg every 3 weeks, pembrolizumab 2 mg/kg every 3 weeks, and chemotherapy (investigator chose between ...
10
New developments in the management of advanced melanoma – role of pembrolizumab
... A more recent randomized, pivotal Phase III study, KEYNOTE-006, investigating pembrolizumab compared to ipilimumab, in the first-line treatment of patients with unresectable stage III or IV advanced ...
9
Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma
... with advanced melanoma in ran- domized controlled ...mutant melanoma, and how its use may be optimized in the future in this ...mutant melanoma in accordance with the licens- ing conditions of ...
10
Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma
... Five hundred and thirty-two patients with histologically- proven diagnosis of advanced melanoma (disease stages III and IV, according to American Joint Committee on Cancer guidelines [21]) were included ...
9
Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)
... Potent anti-tumor effects of FTIs on melanoma cells in vitro motivated clinical exploration of R115777 in patients with advanced melanoma. Although the drug was well tolerated, and potent inhibition ...
8
Clinical utility of nivolumab in the treatment of advanced melanoma
... Abstract: Melanomas are highly immunogenic tumors that evade the immune system by exploiting innate checkpoint pathways, rendering effector T-cells anergic. The immunotherapeutic approach of checkpoint inhibition can ...
13
The efficacy and safety of nivolumab in the treatment of advanced melanoma: a meta-analysis of clinical trials
... limited and no consensus is available on the optimal approach for advanced melanoma treatment. Enrollment in a clinical trial, if available, is the preferred choice. Recently, the PD-1 inhibitor, nivolumab ...
8
Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment
... Oncologist participants were recruited from Lightspeed Research’s All Global physician panel. All Global proprietary panel members are telephone recruited to become members using hospital books and directories, medical ...
11
Methylation dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma
... in melanoma development and ...primary melanoma cell cultures and uncovered two distinct populations, as pre- viously demonstrated by gene expression microarray analysis from our group ...and ...
16
PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma
... Checkpoint inhibitors are revolutionizing treatment options and expectations for patients with melanoma. Ipilimumab, a monoclonal antibody against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), was the ...
14
The combination of vemurafenib and cobimetinib in advanced melanoma
... Malignant melanoma is the most aggressive form of cutaneous malignancy with approximately 132,000 new cases diagnosed globally each ...of melanoma is rising steadily with a doubling of the number of cases ...
28
A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma
... IT Ipi/IL-2 given to patients with non resectable stage III and IV melanoma is well tolerated. Most toxicities were Grade 1 or 2 in nature (fatigue, headache, pain, chills, rash, etc). The clinical benefit rate ...
10
Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma
... cervical lymph node metastases progressing after 4 prior surgical resections and had not received prior systemic therapy for metastatic disease. The patient received a total of 14 administrations of IDD-3 leading to a ...
11
PIM kinases as therapeutic targets against advanced melanoma
... enhance melanoma cell death compared to each single agent, and maintain low activity of AKT and ...adherent melanoma cultures, the alamarBlue assay, SGI-1776, and the PI3Kβ inhibitor AZD6482 in a grid-like ...
16
Clinical aspects of immunotherapy and targeted therapy of advanced melanoma
... Worldwide melanoma incidence has been rising over the past ...of melanoma in 1990 was around 1550 patients, while in 2015 nearly 6000 patients had been diagnosed with melanoma ...with melanoma ...
207
Treating advanced melanoma: current insights and opportunities
... 47. Grosso J, Horak CE, Inzunza D, et al; Keck School of Medicine of the University of Southern California, Los Angeles, CA; Dako North America, Inc., Carpinteria, CA. Association of tumor PD-L1 expres- sion and immune ...
8
Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations
... of advanced melanoma treatment, we sought to further validate the test in an independent cohort of pa- tients with known BRAF mutation status treated with anti-PD-1 therapy in an unselected population ...
8